The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in patients with HER2-neg/low metastatic breast cancer receiving paclitaxel, following an open-label dose optimization.
 
Nuhad K. Ibrahim
No Relationships to Disclose
 
Konstantinos Papadamitriou
No Relationships to Disclose
 
Francois P. Duhoux
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Amgen; Daiichi Sankyo/Astra Zeneca; Pfizer; Roche; Teva
 
Serafin Morales Murillo
No Relationships to Disclose
 
Mafalda Oliveira
Honoraria - Eisai Europe; Gilead Sciences; MSD; Novartis; Pfizer; Roche; SeaGen
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; ITeos Therapeutics; Relay Therapeutics; Roche/Genentech; Seagen
Research Funding - AstraZeneca (Inst); Ayala Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Roche/Genentech (Inst); Seagen (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - AstraZeneca Spain; Eisai; Gilead Sciences; Pierre Fabre
 
Bernard Doger de Spéville
No Relationships to Disclose
 
Danny Houtsma
No Relationships to Disclose
 
Aart Beeker
No Relationships to Disclose
 
Julio Antonio Peguero
Employment - Oncology Consultants
Leadership - Oncology Consultants
Stock and Other Ownership Interests - Oncology Consultants; Roche; Spectrum Pharmaceuticals; Tersera; zogen
Honoraria - Agendia; Guardant Health; Tempus
Speakers' Bureau - Guardant Health; Tempus
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); BerGenBio (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Dizal Pharma (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Genentech/Roche (Inst); Immatics (Inst); ImmunityBio (Inst); Immutep (Inst); IncMed (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Kechow Pharma (Inst); Lilly (Inst); Loxo/Lilly (Inst); Macrogenics (Inst); Mirati Therapeutics (Inst); Natera (Inst); Novartis (Inst); NovoCure (Inst); Sermonix Pharmaceuticals (Inst); Tersera (Inst); Thrive Earlier Detection Corp (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Guardant Health; Tempus
 
Omkar Marathe
No Relationships to Disclose
 
Frederic Triebel
Employment - Immutep
Stock and Other Ownership Interests - Immutep
Patents, Royalties, Other Intellectual Property - Being an inventor on patents on LAG-3 owned by Immutep SAS